Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Clearside Biomedical Inc    CLSD

CLEARSIDE BIOMEDICAL INC (CLSD)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/19/2018 04/20/2018 04/23/2018 04/24/2018 04/25/2018 Date
11.42(c) 11.42(c) 11.21(c) 11.67(c) 11.41 Last
476 167 480 786 289 254 428 701 266 964 Volume
0.00% 0.00% -1.84% +4.10% -2.23% Change
More quotes
Financials (USD)
Sales 2018 0,06 M
EBIT 2018 -73,2 M
Net income 2018 -73,5 M
Finance 2018 15,8 M
Yield 2018 -
Sales 2019 5,79 M
EBIT 2019 -75,4 M
Net income 2019 -75,7 M
Finance 2019 9,02 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 5 948x
EV / Sales2019 60,2x
Capitalization 358 M
More Financials
Company
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011... 
More about the company
Surperformance© ratings of Clearside Biomedical Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CLEARSIDE BIOMEDICAL INC
04/23CLEARSIDE BIOMEDICAL, INC. (NASDAQ : CLSD) Files An 8-K Regulation FD Disclosure
AQ
04/23CLEARSIDE BIOMEDICAL, INC. : Regulation FD Disclosure, Financial Statements and ..
AQ
03/27CLEARSIDE BIOMEDICAL, INC. (NASDAQ : CLSD) Files An 8-K Regulation FD Disclosure
AQ
03/27CLEARSIDE BIOMEDICAL, INC. : Regulation FD Disclosure, Financial Statements and ..
AQ
03/23INSIDER TRADING ACTIVITY CLEARSIDE B : CLSD) – Director Bought 7,500 share..
AQ
03/21Clearside Biomedical to Present at the 17th Annual Needham Healthcare Confere..
GL
03/16CLEARSIDE BIOMEDICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
03/14CLEARSIDE BIOMEDICAL, INC. (NASDAQ : CLSD) Files An 8-K Results of Operations an..
AQ
03/14CLEARSIDE BIOMEDICAL, INC. : Results of Operations and Financial Condition, Fina..
AQ
03/14Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Prov..
GL
More news
Sector news : Bio Therapeutic Drugs
03:11pCurrency and pricing squeeze GSK as new shingles vaccine shines
RE
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/24$CLSD long setup
2
04/24sWings of interest on the long side if and only if they can get thru yday's h.. 
04/23Somewhat Favorable News Coverage Somewhat Unlikely to Impact Clearside Biomed.. 
04/18$CLSD nice continuation 
04/16Clearside Biomedical $CLSD Receives Average Recommendation of “Hold” from Ana.. 
More tweets
Qtime:139
News from SeekingAlpha
04/19Q2 2018 BIOTECH CATALYST WATCHLIST : Phase 2 Clinical Trials 
04/08WEEK 15 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
03/31WEEK 14 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
03/24WEEK 13 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
03/18WEEK 12 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
Chart CLEARSIDE BIOMEDICAL INC
Duration : Period :
Clearside Biomedical Inc Technical Analysis Chart | CLSD | US1850631045 | 4-Traders
Technical analysis trends CLEARSIDE BIOMEDICAL INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 25,5 $
Spread / Average Target 119%
EPS Revisions
Managers
NameTitle
Daniel H. White President, Chief Executive Officer & Director
William D. Humphries Chairman
Charles A. Deignan CFO & Principal Accounting Officer
Glenn Noronha Chief Scientific Officer
Richard L. Beckman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CLEARSIDE BIOMEDICAL INC66.71%358
GILEAD SCIENCES3.31%96 498
VERTEX PHARMACEUTICALS5.89%40 290
REGENERON PHARMACEUTICALS-15.95%34 033
GENMAB20.17%12 599
BEIGENE LTD (ADR)73.75%9 087